Evidence map›Paper›PMID 23999841›Full record

ArticleMedical oncology (Northwood, London, England)2013

Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.

Dawei Li, Zhen Han, Jikai Liu, Xiang Zhang, Juchao Ren, Lei Yan, Hainan Liu, Zhonghua Xu

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03943602 (Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03943602 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)

TypeinterventionalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2019 to 2022Enrolled37ConditionsPenile Squamous Cell CarcinomaArmsCabozantinib
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Prognostic Markers and Trials in Penile Cancer.Urology research & practice · 2023
    Article
  3. Emerging Therapies in Penile Cancer.Frontiers in oncology · 2022
    Review
  4. Article
  5. Article
  6. Tumor Microenvironment in Penile Cancer.Advances in experimental medicine and biology · 2020
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Dawei LiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, 250012, People's Republic of China, lidaweimd@yahoo.cn.
Zhen Han
Jikai Liu
Xiang Zhang
Juchao Ren
Lei Yan
Hainan Liu
Zhonghua Xu
Qilu Hospital of Shandong University · CNBinzhou Medical University · CNMinistry of Education of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatoma-derived growth factor (HDGF) has been verified to serve as a credible prognostic marker for several types of cancers, but its role in urologic carcinomas remains undetermined. In this study, we analyzed the significance of HDGF, as well as its relative factors such as vascular endothelial growth factor-A (VEGF-A) and Ki-67, in penile squamous cell carcinoma (PSCC). Formalin-fixed paraffin-embedded PSCC samples from 54 patients receiving surgery at Qilu Hospital of Shandong University were included in the retrospective study. The expressions of HDGF, VEGF-A, and Ki-67 were detected by immunohistochemistry of a non-biotin polymerized horseradish peroxidase method. The relationships between the expressions of HDGF and VEGF-A, Ki-67 were assessed. Moreover, their correlations with clinical pathologic characteristics and disease prognosis were, respectively, evaluated. HDGF, VEGF-A, and Ki-67 were positively expressed in 28 (51.9%), 29 (53.7%), and 26 (48.1%) patients, respectively. The expressions of VEGF-A and Ki-67 were closely correlated with PSCC type (P < 0.05). A statistically significant relationship between the expressions of HDGF and VEGF-A in PSCC was observed (P = 0.03). Patients with symptom interval of more than 6 months had a significantly poorer survival rate than those with symptom interval less than 6 months (43.3 vs. 70.8%, P = 0.043). Patients with positive HDGF expression also showed a significantly poorer survival rate than those with negative HDGF expression (39.3 vs. 73.1%, P = 0.013). Logistic regression demonstrated that the expression level of HDGF was an independent predictor for the prognosis of postoperative patients. The expression of HDGF significantly correlated with VEGF-A, but not Ki-67 expression. Overexpression of HDGF, rather than VEGF-A or Ki-67, was confirmed to be an independent prognosticator of poor outcome for PSCC patients.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellCell NucleusHumansIntercellular Signaling Peptides and ProteinsKi-67 AntigenMaleMiddle AgedPenile NeoplasmsPrognosisRetrospective StudiesSurvival RateUp-RegulationBiomarkers, Tumorhepatoma-derived growth factorIntercellular Signaling Peptides and ProteinsKi-67 AntigenVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID23999841
OpenAlexW2045498502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.